ROSEVILLE, Minn. -- On February 26, 2002 the U.S.
Patent and Trademark Office granted Parker Hughes Institute a patent (U.S.
patent No. 6,350,736) for Stampidine, a new anti-AIDS drug developed at the
Parker Hughes Institute has completed all pre-clinical research and
development related to Stampidine and is getting ready to seek FDA approval to
initiate clinical trials. Parker Hughes Institute expects to receive that
approval and begin clinical trials of Stampidine within the next three to six
Minnesota Comprehensive Care Center, the HIV/AIDS clinic operated by the
Institute, has been temporarily closed so that the staff may focus on all the
necessary preparations needed to initiate the Stampidine clinical trial.
"There's a lot of hard work that needs to be done in order to prepare for
this clinical trial and we have made the decision that for now our HIV clinic
will focus solely on the Stampidine trial so that we can continue to develop
this life saving anti-AIDS drug without delay," said Fatih Uckun, President
and Director of Parker Hughes Institute.
SOURCE Parker Hughes Institute
Web Site: http://www.parkerhughes.org